Concepedia

Reto Ritschard

RR

Statistics

Publications

13

Citations

854

H-Index

12

Active since

1999

Affiliations

University Hospital of Basel(Current)

University of Basel

Kantonsspital Aarau

Swiss Group For Clinical Cancer Research

University Hospital of Zurich

Reto Ritschard is an author at University Hospital of Basel specializing in medicine, radiation oncology, and immunology.

ORCID

Top concepts

Publications per year

1999–2023

13

Publications

13

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study

Christoph Mamot, Reto Ritschard, Andreas Wicki et al. · The Lancet Oncology · 2012 · 233 citations

, , +7

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

Chiara Tarantelli, Eugenio Gaudio, Alberto J. Arribas et al. · Clinical Cancer Research · 2017 · 117 citations

Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth

Andreas Wicki, Christoph Rochlitz, Annette Orleth et al. · Clinical Cancer Research · 2011 · 91 citations

EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells

Christoph Mamot, Reto Ritschard, Willy Küng et al. · Journal of drug targeting · 2006 · 67 citations

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Andreas Wicki, Nicholas F. Brown, Alexandros Xyrafas et al. · European Journal of Cancer · 2018 · 62 citations

, , +8

1–5 of 13